Pharmacological Ascorbate for Lung Cancer

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title: A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer

Status Completed

Clinical Trial Summary

This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.

Clinical Trial Description

Standard treatment for non-small cell lung cancer (NSCLC) involves a combined therapy of paclitaxel and carboplatin. These drugs are administered once every 21 days. This study adds high dose ascorbic acid (75g per infusion) twice per week for up to 4 cycles of therapy.

Participants will:

• receive high doses of intravenous (IV) ascorbate two times a week during each 3 week chemotherapy.

• have blood samples drawn to measure blood ascorbate levels once every 21 days

• have blood samples drawn to measure iron and ferritin levels before treatment, then on cycles 1 and 3.

The active therapy portion of this study lasts for 4 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

• NCT number: NCT02420314
• Study type: Interventional
• Source: University of Iowa
• Status: Completed
• Phase: Phase 2
• Start date: April 2015
• Completion date: August 27, 2022